Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra SC in Adult RA
NCT01988012Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity at Week 24, Change From Baseline in CDAI at Week 24 and 12 more. Started Jan 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01988012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01988012.